These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25495659)

  • 21. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease.
    Tsumura M; Kinouchi T; Ono S; Nakajima T; Komoda T
    Clin Chim Acta; 2001 Dec; 314(1-2):27-37. PubMed ID: 11718676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma concentrations of non-esterified fatty acids in chronic renal failure in the United Arab Emirates.
    Gillett MP; Obineche EN; Khan ST; Abdulle AM
    Saudi Med J; 2004 Nov; 25(11):1611-6. PubMed ID: 15573187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient remnant removal disease in acute fatty liver of pregnancy.
    Wetzka B; Hoffmann MM; Friedrich I; Baumstark MW; Zahradnik HP; März W; Winkler K
    Hypertens Pregnancy; 2004; 23(2):143-53. PubMed ID: 15369648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased lipoprotein-remnant formation in chronic renal failure.
    Nestel PJ; Fidge NH; Tan MH
    N Engl J Med; 1982 Aug; 307(6):329-33. PubMed ID: 7088097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure.
    Kimak E; Ksiazek A; Solski J
    Clin Chem Lab Med; 2006; 44(1):64-9. PubMed ID: 16375588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDL and HDL subclass distribution in patients with end-stage renal diseases.
    Alabakovska SB; Todorova BB; Labudovic DD; Tosheska KN
    Clin Biochem; 2002 May; 35(3):211-6. PubMed ID: 12074829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
    Nassiri AA; Hakemi MS; Soulati M; Marashian M; Rahbar K; Azizi F
    Iran J Kidney Dis; 2009 Jul; 3(3):162-7. PubMed ID: 19617666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
    Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
    Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?
    Gluba-Brzózka A; Franczyk B; Banach M; Rysz-Górzyńska M
    Int Urol Nephrol; 2017 Jan; 49(1):155-164. PubMed ID: 27942970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Very low density lipoproteins and subclasses of intermediate density lipoproteins in postmenopausal women].
    Berg G; Halperín H; Siseles N; Wikinski R
    Medicina (B Aires); 1996; 56(5 Pt 1):479-86. PubMed ID: 9239883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of glutathione-S-transferase gene polymorphism and lipoprotein subclasses in hemodialysis patients.
    Vekic J; Zeljkovic A; Jelic-Ivanovic Z; Damjanovic T; Suvakov S; Matic M; Savic-Radojevic A; Simic T; Spasojevic-Kalimanovska V; Gojkovic T; Spasic S; Dimkovic N
    Clin Biochem; 2014 Apr; 47(6):398-403. PubMed ID: 24291050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of lipoprotein remnants in patients with chronic renal failure.
    Ron D; Oren I; Aviram M; Better OS; Brook JG
    Atherosclerosis; 1983 Jan; 46(1):67-75. PubMed ID: 6838695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disturbed lipids, lipoproteins and triglyceride-rich lipoproteins as well as fasting and nonfasting non-high-density lipoprotein cholesterol in post-renal transplant patients.
    Kimak E; Ksiazek A; Baranowicz-Gaszczyk I; Solski J
    Ren Fail; 2007; 29(6):705-12. PubMed ID: 17763166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.